Pathophysiology of pulmonary arterial hypertension

Seminars in Cardiothoracic and Vascular Anesthesia

Volumn 11, Issue 2, 2007, Pages 104-109

  Jain, Suma ^a   Ventura, Hector ^a   DeBoisblanc, Ben ^b  

^a OCHSNER CLINIC FOUNDATION   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Endothelial disfunction; Nitric oxide pathway; Pulmonary arterial hypertension

Indexed keywords

ADRENOMEDULLIN; ARGININE; CITRULLINE; CYCLIC GMP; DIMETHYLARGININASE; GUANYLATE CYCLASE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; PHOSPHODIESTERASE; PROSTACYCLIN; SEROTONIN; THROMBOXANE;

ARTICLE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; FUNCTIONAL DISEASE; HEART RIGHT VENTRICLE FAILURE; HEREDITY; HISTOPATHOLOGY; HUMAN; LUNG ARTERY PRESSURE; LUNG ENDOTHELIUM; LUNG VASCULAR RESISTANCE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PATHOGENESIS; PULMONARY HYPERTENSION; SMOOTH MUSCLE; STRUCTURE ANALYSIS; THROMBOEMBOLISM; THROMBOSIS; VASOCONSTRICTION;

HUMANS; HYPERTENSION, PULMONARY;

EID: 34249805714     PISSN: 10892532     EISSN: None     Source Type: Journal    
DOI: 10.1177/1089253207301732     Document Type: Article

References (46)

1. Simonneau G., Galie N., Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004 ; 43 (suppl): 5-12.
2. Budhiraja R., Tuder RM, Hassoun PM Endothelial dysfunction in pulmonary hypertension. Circulation. 2004 ; 109: 159-165.
3. Kasper M. Phenotypic characterization of pulmonary arteries in normal and diseased lung. Chest. 2005 ; 128 (Suppl): 547S - 552S.
4. Keil A., Blom IE, Goldschmeding R., et al. Nitric oxide down-regulates connective tissue growth factor in rat mesangial cells. Kidney Int. 2002 ; 62: 401-411.
5. Emerson M., Momi S., Paul W., et al. Endogenous nitric oxide acts as a natural antithrombotic agent in vivo by inhibiting platelet aggregation in the pulmonary vasculature. Thromb Haemost. 1999 ; 81: 961-966.
6. Morris CR, Kate GJ, Poliakovic M., et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA. 2005 ; 294: 81-90.
7. Morris CR, Morris SM Jr, Hagar W., et al. Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med. 2003 ; 168: 63-69.
8. Mehta S., Stewart DJ, Langleben D., et al. Short-term pulmonary vasodilation with L-arginine in pulmonary hypertension. Circulation. 1995 ; 92: 1539-1545.
9. Chou TF, Wu MS, Chien CT, et al. Enhanced expression of nitric oxide synthase in the early stage after increased pulmonary blood flow in rats. Eur J Cardiothorac Surg. 2002 ; 21: 331-336.
10. Giaid A., Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med. 1995 ; 333: 214-221.
11. Mason NA, Springall DR, Burke M., et al. High expression of endothelial nitric oxide synthase in plexiform lesions of pulmonary hypertension. J Pathol. 1998 ; 185: 313-318.
12. Demoncheaux EA, Higenbottam TW, Kiely DG, et al. Decreased whole body endogenous nitric oxide production in patients with primary pulmonary hypertension. J Vasc Res. 2005 ; 42: 133-136.
13. Kielstein JT, Bode-Boger SM, Hesse G., et al. Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol. 2005 ; 25: 1414-1418.
14. Galie N., Ghofrani HA, Torbicki A., et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005 ; 353: 2148-2157.
15. Geraci MW, Gao B., Shepherd DC, et al. Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension. J Clin Invest. 1999 ; 103: 1509-1515.
16. Tahara N., Kai H., Niivama H., et al. Repeated gene transfer of naked prostacyclin synthase plasmid into skeletal muscles attenuates monocrotaline-induced pulmonary hypertension and prolongs survival in rats. Hum Gene Ther. 2004 ; 15: 1270-1278.
17. Tuder RM, Cool CD, Geraci MW, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med. 1999 ; 159: 1925-1932.
18. Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med. 1992 ; 327: 70-75.
19. Katugampola SD, Davenport AP Thromboxane receptor density is increased in human cardiovascular disease with evidence for inhibition at therapeutic concentrations by the AT(1) receptor antagonist losartan. Br J Pharmacol. 2001 ; 134: 1385-1392.
20. Rich S., Hart K., Kieras K., et al. Thromboxane synthetase inhibition in primary pulmonary hypertension. Chest. 1987 ; 91: 356-360.
21. Hassoun PM, Thappa V., Landman MJ, et al. Endothelin 1: mitogenic activity on pulmonary artery smooth muscle cells and release from hypoxic endothelial cells. Proc Soc Exp Biol Med. 1992 ; 199: 165-170.
22. Dupuis J. Endothelin-receptor antagonists in pulmonary hypertension. Lancet. 2001 ; 358: 1113-1114.
23. Langleben D., Dupuis J., Langleben I., et al. Etiology-specific endothelin-1 clearance in human precapillary pulmonary hypertension. Chest. 2006 ; 129: 689-695.
24. Giaid A., Yanagisawa M., Langleben D., et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993 ; 328: 1732-1749.
25. Galie N., Manes A., Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res. 2004 ; 61: 227-237.
26. Jasmin JF, Lucas M., Cernacek P., et al. Effectiveness of a nonselective ET(A/B) and a selective ET(A) antagonist in rats with monocrotaline-induced pulmonary hypertension. Circulation. 2001 ; 103: 314-318.
27. Weir EK, Hong Z., Varghese A. The serotonin transporter: a vehicle to elucidate pulmonary hypertension? Circ Res. 2004 ; 94: 1152-1144.
28. Herve P., Launay JM, Scrobohaci ML, et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med. 1995 ; 99: 249-254.
29. Kramer MS, Lane DA Aminorex, dexfenfluramine, and primary pulmonary hypertension. J Clin Epidemiol. 1998 ; 51: 361-364.
30. Abenhaim L., Moride Y., Brenot F., et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996 ; 335: 609-616.
31. Tuder RM, Flook BE, Voelkel NF Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia: modulation of gene expression by nitric oxide. J Clin Invest. 1995 ; 95: 1798-1807.
32. Schermuly RT, Dony E., Ghofrani HA, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest. 2005 ; 115: 2811-2821.
33. Kakishita M., Nishikimi T., Okano Y., et al. Increased plasma levels of adrenomedullin in patients with pulmonary hypertension. Clin Sci. 1999 ; 96: 33-39.
34. Farber HW, Loscalzo J. Prothrombotic mechanisms in primary pulmonary hypertension. J Lab Clin Med. 1999 ; 134: 561-566.
35. Caramuru LH, Maeda NY, Bydlowski SP, et al. Age-dependent likelihood of in situ thrombosis in secondary pulmonary hypertension. Clin Appl Thromb Hemost. 2004 ; 10: 217-223.
36. Herve P., Humbert M., Sitbon O., et al. Pathobiology of pulmonary hypertension: the role of platelets and thrombosis. Clin Chest Med. 2001 ; 22: 451-458.
37. Dresdale DT, Mitchom RJ, Schultz M. Recent studies in primary pulmonary hypertension, including pharmacodynamic observations on pulmonary vascular resistance. Bull N Y Acad Med. 1954 ; 30: 195-207.
38. Loyd JE Genetics and pulmonary hypertension. Chest. 2002 ; 122: 284S - 286S.
39. Rich S., Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med. 1987 ; 107: 216-223.
40. Grunig E., Mereles D., Arnold K., et al. Primary pulmonary hypertension is predominantly a hereditary disease. Chest. 2002 ; 121 (Suppl): 81S - 82S.
41. Nichols WC, Koller DL, Slovis B., et al. Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31-32. Nat Genet. 1997 ; 15: 277-280.
42. Lane KB, Machado RD, Pauciulo MW, et al. Heterozygous germline mutations in a TGF-β receptor, BMPR2, are the cause of familial primary pulmonary hypertension. The International PPH Consortium. Nat Genet. 2000 ; 26: 81-84.
43. Newman JH, Trembath RC, Morse JA, et al. Genetic basis of pulmonary arterial hypertension: current understanding and future directions. J Am Coll Cardiol. 2004 ; 43 (Suppl S). 33S - 39S.
44. Elliott CG Genetics of pulmonary arterial hypertension: current and future implications. Semin Respir Crit Care Med. 2005 ; 26: 365-371.
45. Humbert M., Deng Z., Simonneau G., et al. BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives. Eur Respir J. 2002 ; 20: 518-523.
46. Elliott CG, Glissmeyer EW, Havlena GT, et al. Relationship of BMPR2 mutations to vasoreactivity in pulmonary arterial hypertension. Circulation. 2006 ; 113: 2509-2515.